Drugs, Parkinson's disease and parkinsonian syndroms: Recent advances in pharmacovigilance;Médicaments, maladie de Parkinson et syndromes parkinsoniens: Actualités de pharmacovigilance

Therapie

Volumn 61, Issue 1, 2006, Pages 29-38

  Montastruc, Jean Louis ^a,b   Sommet, Agnès ^a,b   Olivier, Pascale ^a,b   Bagheri, Haleh ^a,b   Gony, Mireille ^a,b   Lapeyre Mestre, Maryse ^a,b   Brefel Courbon, Christine ^a,b   Ferreira, Joachim ^c   Schmitt, Laurent ^b   Senard, Jean Michel ^a,b   Rascol, Olivier ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

Author keywords

Adverse drug reactions; Dopamine agonists; Levodopa; Parkinson's disease; Pharmacovigilance

Indexed keywords

ALIZAPRIDE; APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CABERGOLINE; CLOZAPINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; ENTACAPONE; LEVODOPA; LISURIDE; METOCLOPRAMIDE; METOPIMAZINE; OLANZAPINE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; RISPERIDONE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL; TRIMETAZIDINE; VALPROIC ACID; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

CONFERENCE PAPER; DISEASE DURATION; DRUG SURVEILLANCE PROGRAM; DYSAUTONOMIA; HUMAN; HYPERSEXUALITY; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SOMNOLENCE; VALVULAR HEART DISEASE; ARTICLE; FRANCE; PRESCRIPTION; STANDARD; STATISTICS; TRAFFIC ACCIDENT;

ACCIDENTS, TRAFFIC; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; FRANCE; HUMANS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PRESCRIPTIONS, DRUG;

EID: 33747038163     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006011     Document Type: Conference Paper

References (58)

1. Montastruc JL. Recent advances in the clinical pharmacology of Parkinson's disease. Therapie 1991; 46: 293-303
2. Goetz GB, De Long Mr, Penn R, et al. Neurosurgical horizons in Parkinson's disease. Neurology 1993; 43: 1-7
3. e édition, 1988, 1127-1156
4. Montastruc JL, Rascol O, Senard JM. New directions in the drug treatment of Parkinson's disease. Drugs Aging 1996; 9: 169-184
5. Goetz CJ, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatment of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539
6. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who where treated with ropinirole or levodopa. N Engl J Med 2000; 18: 1484-1491
7. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (largo, lasting effect in agent therapy with rasagiline given once daily study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954
8. Montastruc JL. La Pharmacologie Sociale : une nouvelle branche de la Pharmacologie Clinique. Therapie 2002; 57: 420-426
9. Frucht S, Rogers JD, Greene PB, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1910
10. Chaudhuri KR, Pal S, Brefel-Courbon C. "Sleep attacks" or "unintended sleep episodes" occur with dopamine agonists. Is this a class effect? Drug Saf 2002; 25: 473-483
11. Nausieda PA, Glantz R, Weber S, et al. Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 1984; 40: 271-277
12. Bares M, Kanowsky P, Rektor I. Excessive daytime sleepiness and sleep attacks induced by entacapone. Fundam Clin Pharmacol 2003; 17: 113-116
13. Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-667
14. Brodsky MA, Godbold J, Roth T, et al. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-672
15. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and anti-parkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001; 24: 181-183
16. Etminan M, Samii A, Takkouche B, et al. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease. A meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863-868
17. Andreu N, Challe JJ, Senard JM, et al. L-dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999; 22: 15-23
18. Ferreira JJ, Galtizky M, Thalamas C, et al. Effect of ropinirole on sleep onset: randomized, placebo-controlled study in healthy volunteers. Neurology 2002; 58: 460-462
19. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2002; 18: 287-293
20. Billard M. Le sommeil normal et pathologique. Ed. Masson, Paris 1994, 1 vol, 570 pp
21. Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77: 1280-1286
22. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-1183
23. Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-304
24. Afssaps. Rapport de la Commission Nationale de PharmacoVigilance sur pergolide et valvulopathies cardiaques du 23 novembre 2004. Available on http://agmed.sante.gouv.fr/pdf/5/vigi25.pdf
25. Van Camp G, Flamez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-861
26. Prescrire Redaction. Fibrosis due to ergot derivatives: exposure to risk should be weighed up. Prescrire Int 2002; 11: 186-189
27. Fitzgerald LW, Burin TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine-phentermine. N Engl J Med 1997; 37: 581-588
28. Rothmann R, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT 2 B receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications. Circulation 2000; 102: 2826-2841
29. Montastruc JL, Pathak A, Bagheri H. Valvulopathies sous pergolide : la saga des fibroses dues aux dérivés de l'ergot de seigle continue ! Rev Neurol (Paris) 2004; 160: 19-21
30. Fundacio Institut Catala de Farmacologia. Gasto en medicamentos y innovation terapeutica. Butteli Groc 2004; 17: 13-18
31. Prescrire Redaction. Hypersexualité due aux médicaments dopaminergiques. Rev Prescrire 2005; 25: 434-435
32. Utti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989; 12: 375-383
33. Kanovsky P, Bares M, Pohanka M, et al. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 2002; 249: 112-114
34. Jimenez-Jimenez FJ, Sayed Y, Garcia-Soldevilla MA, et al. Possible zoophilia associated with dopaminergic therapy in Parkinson's disease. Ann Pharmacother 2002; 36: 1178-1179
35. Berger Ch, Mehrhoff FW, Beier KM, et al. Sexual delinquency and Parkinson's disease. Nervenarzt 2003; 74: 370-375
36. Riley D. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 2002; 25: 234-237
37. Paus JG, Everitt BJ. The psychopharmacology of sexual behaviour. In: Psychopharmacology: the fourth generation of progress, edited by FE Bloom and DJ Kupfer. Raven Press, Ltd. New-York 1995: 743-758
38. Seedat S, Kesler S, Niehaus D, et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000; 11: 185-186
39. Samanta J, Stacy M. Compulsive gambling with dopaminergic therapy in Parkinson's disease. Mov Disord 2000; 15 (suppl 3): 125 [letter]
40. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioural manifestation of pharmacologic treatment? Mov Disord 2000; 15: 869-872
41. Gschwandtner U, Aston J, Renaud S, et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24: 170-172
42. Avanzi M, Uber E, Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 2004; 25: 98-101
43. Kurlan R. Disabling repetitive behaviours in Parkinson's disease. Mov Disord 2004; 19: 433-469
44. Montastruc JL, Schmitt L, Bagheri H. Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine. Rev Neurol (Paris) 2003; 159: 441-443
45. Prescrire Redaction. Des médicaments qui poussent au jeu pathologique. Rev Prescrire 2001; 21: 675 [letter]
46. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorders. Eur J Pharmacol 1999; 375: 13-30
47. Perez de Castro I, Ibanez A, Torres P, et al. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997; 7: 345-348
48. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604
49. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293-306
50. Nguyen N, Pradel V, Micalleff J, et al. Les syndromes parkinsoniens médicamenteux. Therapie 2004; 59: 105-112
51. Prescrire Rédaction. Effets extrapyramidaux des antidépresseurs inhibiteurs de la recapture de la sérotonine. Rev Prescrire 2001; 21: 201-203
52. Van de Vijver DA, Roos RA, Jansen PA, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002; 54: 167-170
53. Gony M, Lapeyre-Mestre M, Montastruc JL, and the French Network of Regional Pharmacovigilance Centers. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26: 142-145
54. Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 1995; 10: 355-357
55. Masmoudi K, Gras-Champel V, Bonnet I, et al. Démence et troubles extrapyramidaux sous acide valproïque au long cours. Therapie 2000; 55: 629-634
56. Redaction Prescrire. Syndrome démentiel reversible dû à l'acide valproïque. Rev Prescrire 2003; 23: 835 [letter]
57. Marti-Masso JF. Parkinsonismo por trimetazidine. Neurologia 2004; 19: 392-395
58. Sommet A, Azais-Vuillemin C, Bagheri H, et al. Trimetazidine: a new cause for drug-induced parkinsonism? Mov Disord 2005; 20 (8): 1080-1081 [letter]